Defining patient risks from expanded preventive therapies
- 1 June 2000
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 85 (12), 15-19
- https://doi.org/10.1016/s0002-9149(00)00946-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Association of nonalcoholic fatty liver disease with insulin resistanceThe American Journal of Medicine, 1999
- Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central MassachusettsPharmacoepidemiology and Drug Safety, 1999
- Acute Cholestatic Hepatitis Associated With PravastatinAmerican Journal of Gastroenterology, 1999
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatinDigestive Diseases and Sciences, 1994
- Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatinThe American Journal of Medicine, 1991
- Biochemical Changes and Morphological Alterations of the Liver in Guinea‐Pigs after Administration of Simvastatin (HMG CoA Reductase‐Inhibitor)Basic & Clinical Pharmacology & Toxicology, 1990
- Preclinical evaluation of lovastatinThe American Journal of Cardiology, 1988
- Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activityFEBS Letters, 1976
- Effect on Hepatic Morphology of Treatment of Obesity by Fasting, Reducing Diets and Small-Bowel BypassNew England Journal of Medicine, 1970